JP4291417B2 - 放射性同位体によって標識されたペプチドのための放射線保護剤 - Google Patents

放射性同位体によって標識されたペプチドのための放射線保護剤 Download PDF

Info

Publication number
JP4291417B2
JP4291417B2 JP50281899A JP50281899A JP4291417B2 JP 4291417 B2 JP4291417 B2 JP 4291417B2 JP 50281899 A JP50281899 A JP 50281899A JP 50281899 A JP50281899 A JP 50281899A JP 4291417 B2 JP4291417 B2 JP 4291417B2
Authority
JP
Japan
Prior art keywords
composition
radiolabeled
povidone
peptide
mci
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP50281899A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002516612A5 (https=
JP2002516612A (ja
Inventor
ショチャット，ダン
エス．，ケー． チャン，アルバート
ジェイ． バックレー，マイケル
Original Assignee
スミスクライン ビーチャム コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スミスクライン ビーチャム コーポレーション filed Critical スミスクライン ビーチャム コーポレーション
Publication of JP2002516612A publication Critical patent/JP2002516612A/ja
Publication of JP2002516612A5 publication Critical patent/JP2002516612A5/ja
Application granted granted Critical
Publication of JP4291417B2 publication Critical patent/JP4291417B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP50281899A 1997-06-03 1998-06-03 放射性同位体によって標識されたペプチドのための放射線保護剤 Expired - Fee Related JP4291417B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4838797P 1997-06-03 1997-06-03
US60/048,387 1997-06-03
US08/918,525 1997-08-21
US08/918,525 US5961955A (en) 1997-06-03 1997-08-21 Radioprotectant for peptides labeled with radioisotope
PCT/US1998/011428 WO1998055154A1 (en) 1997-06-03 1998-06-03 Radioprotectant for peptides labeled with radioisotope

Publications (3)

Publication Number Publication Date
JP2002516612A JP2002516612A (ja) 2002-06-04
JP2002516612A5 JP2002516612A5 (https=) 2005-12-22
JP4291417B2 true JP4291417B2 (ja) 2009-07-08

Family

ID=26726075

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50281899A Expired - Fee Related JP4291417B2 (ja) 1997-06-03 1998-06-03 放射性同位体によって標識されたペプチドのための放射線保護剤

Country Status (14)

Country Link
US (2) US5961955A (https=)
EP (1) EP1003560B1 (https=)
JP (1) JP4291417B2 (https=)
AT (1) ATE249845T1 (https=)
AU (1) AU743823B2 (https=)
CA (1) CA2290987A1 (https=)
DE (1) DE69818272T2 (https=)
DK (1) DK1003560T3 (https=)
ES (1) ES2212304T3 (https=)
IL (1) IL133271A (https=)
NO (1) NO315693B1 (https=)
NZ (1) NZ502029A (https=)
PT (1) PT1003560E (https=)
WO (1) WO1998055154A1 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5961955A (en) * 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
US6315979B1 (en) * 1998-06-02 2001-11-13 The Dow Chemical Company Radioiodinated sulfonated phenols for brachytherapy
US20020102208A1 (en) * 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
KR100330733B1 (ko) * 1999-11-30 2002-04-03 노광 폴리에틸렌글리콜포스페이트, 그의 합성방법 및 그를방사능보호제로 사용하는 방법
US6683162B2 (en) * 2000-09-15 2004-01-27 Sloan Kettering Institute Of Cancer Research Targeted alpha particle therapy using actinium-255 conjugates
CZ20032597A3 (cs) * 2001-02-26 2004-12-15 Bristol-Myers Squibb Pharma Company Analogy kyseliny askorbové pro metaloradiofarmaceutika
US6972324B2 (en) * 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
US7238338B1 (en) * 2001-06-22 2007-07-03 Triumf System and method for the large scale labeling of compounds with radiohalogens
US7344702B2 (en) 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
WO2003105762A2 (en) * 2002-06-14 2003-12-24 Actinium Pharmaceuticals Ltd. Treating disease using radium-225
US7018614B2 (en) * 2002-11-05 2006-03-28 Eastern Isotopes, Inc. Stabilization of radiopharmaceuticals labeled with 18-F
JP4741242B2 (ja) 2002-11-26 2011-08-03 アボット バイオセラピューティクス コーポレイション 新脈管形成を調節するα５β１インテグリンへのキメラ及びヒト化抗体
EP1444990A1 (en) * 2003-02-07 2004-08-11 Amersham plc Improved Radiometal Complex Compositions
US7485283B2 (en) * 2004-04-28 2009-02-03 Lantheus Medical Imaging Contrast agents for myocardial perfusion imaging
ES2475207T3 (es) 2004-07-15 2014-07-10 Tetralogic Pharmaceuticals Corporation Compuestos de unión a IAP
MX2007010371A (es) * 2005-02-25 2008-01-11 Tetralogic Pharmaceuticals Inhibidores dimericos iap.
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
CA2617642A1 (en) * 2005-08-09 2007-02-22 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
JP5452223B2 (ja) * 2006-07-24 2014-03-26 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ阻害剤
MX2009000824A (es) * 2006-07-24 2009-02-04 Tetralogic Pharmaceuticals Cor Antagonistas dimericos de las proteinas inhibidoras de la apoptosis.
US20100143499A1 (en) * 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014240A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
JP5297815B2 (ja) 2007-01-26 2013-09-25 株式会社ポーラファルマ 医薬組成物
CN101678082B (zh) 2007-03-26 2013-06-19 再生医药有限公司 使用cxcl9和抗cxcl9抗体促进骨髓保护和再生的方法
WO2009108376A2 (en) 2008-02-29 2009-09-03 Lantheus Medical Imaging, Inc. Contrast agents for applications including perfusion imaging
KR20110097772A (ko) * 2008-11-17 2011-08-31 제넨테크, 인크. 생리적 조건하에 거대분자의 응집을 감소시키는 방법 및 제제
KR20160030589A (ko) 2009-04-15 2016-03-18 랜티우스 메디컬 이메징, 인크. 아스코르브산을 사용한 방사성 약제 조성물의 안정화
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
DK3323810T3 (da) 2010-02-08 2022-03-28 Lantheus Medical Imaging Inc Automatiseret reaktionssystem, kassette og indretning til syntese af billeddannelsesmidler
GB201013808D0 (en) * 2010-08-18 2010-09-29 Ge Healthcare Ltd Peptide radiotracer compositions
AU2013203000B9 (en) 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
CA2901231C (en) * 2013-02-15 2020-06-23 Thomas Jefferson University Kit comprising lyophilized compositions for tumor imaging
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) * 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
EP3094391B1 (en) * 2014-01-17 2024-11-20 Repligen Corporation Sterilizing chromatography columns
IL237852A0 (en) 2015-03-19 2016-03-24 Yeda Res & Dev Antibodies against amphigoline, medical preparations containing them and their use
TWI799366B (zh) * 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
WO2017155937A1 (en) * 2016-03-07 2017-09-14 Actinium Pharmaceuticals, Inc. Stabilized radiolabeled anti-cd45 immunoglobulin compositions
US11339221B2 (en) 2017-11-01 2022-05-24 Tufts Medical Center, Inc. Bispecific antibody constructs and methods of use
CN113660927A (zh) * 2019-04-23 2021-11-16 安进公司 使用低分子量聚乙烯吡咯烷酮（pvp）降低高浓度蛋白质配制品的黏度
US12043671B2 (en) 2021-06-16 2024-07-23 Gundersen Lutheran Medical Foundation, Inc. Antibodies targeting an amphiregulin-derived cell surface neo-epitope
WO2024259346A1 (en) 2023-06-16 2024-12-19 Progenics Pharmaceuticals, Inc Improved synthesis of the prostate specific membrane antigen (psma) radiolabeled inhibitor [18f]dcfpyl

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE933885C (de) * 1952-06-22 1955-10-06 Helmut Richard Dr Kanitz Verfahren zur Herstellung kolloidaler Loesungen radioaktiver Metalle wie radioaktiver Goldisotope
US4421735A (en) * 1980-04-17 1983-12-20 The Massachusetts General Hospital Radiolabeled diagnostic compositions and method for making the same
US4427631A (en) * 1982-05-27 1984-01-24 Euroceltique, S.A. Povidone irradiation
US4411881A (en) * 1982-07-12 1983-10-25 New England Nuclear Corporation Composition and method for stabilizing radiolabeled compounds using thiocarbonylated diethylenetriamines
EP0111414A3 (en) * 1982-12-08 1985-05-02 Mallinckrodt, Inc. (a Delaware corporation) Radiographic imaging agents
US4676979A (en) * 1984-12-31 1987-06-30 Eastern Virginia Medical Authority/Med. Ctr. Hosp. Method of protecting animals against ionizing radiation
US5393512A (en) * 1985-01-14 1995-02-28 Vanderheyden; Jean-Luc Stable therapeutic radionuclide compositions and methods for preparation thereof
US5061641A (en) * 1988-04-01 1991-10-29 Immunomedics, Inc. Method for radiolabeling proteins
RO103925B1 (ro) * 1989-02-27 1992-04-26 Institutul De Chimie Macromoleculara "P.Poni" Derivat de polivinilpirolidona si procedeu de preparare
CA2066779A1 (en) * 1989-09-22 1991-03-23 Jean-Luc Vanderheyden Stable therapeutic radionuclide compositions and methods for preparation thereof
US5011676A (en) * 1990-03-27 1991-04-30 Thomas Jefferson University Method to directly radiolabel antibodies for diagnostic imaging and therapy
WO1993002652A2 (en) * 1991-08-01 1993-02-18 Hybritech Incorporated Modified haptens useful as imaging and therapeutic agents
DK0600992T3 (da) * 1991-08-29 2000-10-09 Mallinckrodt Medical Inc Anvendelse af gentissyre eller gentisylalkohol til stabilisering af radiomærkede peptider og proteiner
CA2105402C (en) * 1992-04-30 2000-04-04 Roger M. Price Radiolabelled compound formulations
WO1994002174A1 (fr) * 1992-07-28 1994-02-03 Toray Industries, Inc. Immunocomplexe
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5961955A (en) * 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope

Also Published As

Publication number Publication date
AU743823B2 (en) 2002-02-07
EP1003560A1 (en) 2000-05-31
AU8057098A (en) 1998-12-21
DE69818272T2 (de) 2004-07-01
WO1998055154A9 (en) 1999-04-08
DK1003560T3 (da) 2003-12-01
ATE249845T1 (de) 2003-10-15
NZ502029A (en) 2001-12-21
ES2212304T3 (es) 2004-07-16
DE69818272D1 (de) 2003-10-23
EP1003560B1 (en) 2003-09-17
CA2290987A1 (en) 1998-12-10
IL133271A0 (en) 2001-04-30
JP2002516612A (ja) 2002-06-04
NO995906L (no) 1999-12-03
NO315693B1 (no) 2003-10-13
NO995906D0 (no) 1999-12-02
IL133271A (en) 2004-06-01
US6338835B1 (en) 2002-01-15
PT1003560E (pt) 2004-02-27
WO1998055154A1 (en) 1998-12-10
US5961955A (en) 1999-10-05

Similar Documents

Publication Publication Date Title
JP4291417B2 (ja) 放射性同位体によって標識されたペプチドのための放射線保護剤
US6024938A (en) Lyophilized imaging agent formulation comprising a chemotactic peptide
TWI283178B (en) Method and kit for efficient radiolabeling of proteins with therapeutic radioisotopes
US5605671A (en) Radiolabeled neutrophil activating peptides for imaging
EP0670736B1 (en) Labelled interleukin-8 and medical uses thereof
Rennen et al. Specific and rapid scintigraphic detection of infection with 99mTc-labeled interleukin-8
RU2741794C2 (ru) Радиофармацевтические растворы с предпочтительными свойствами
CA2279349C (en) Ascorbate-stabilized radiopharmaceutical method and composition
van der Laken et al. Imaging of infection in rabbits with radioiodinated interleukin-1 (α and β), its receptor antagonist and a chemotactic peptide: a comparative study
DeNardo et al. Are radiometal-labeled antibodies better than iodine-131–labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67–, iodine-131–, and yttrium-90–labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma
US20100047167A1 (en) Combination therapy in the treatment of cancer
CN100586484C (zh) 用于放射治疗软组织疾病的钍-227
Adams et al. Effect of mass of 111In-benzyl-EDTA monoclonal antibody on hepatic uptake and processing in mice
Signore et al. Biological imaging for the diagnosis of inflammatory conditions
Signore et al. [68Ga] Ga-interleukin-2 for imaging activated T-lymphocytes: biochemical characterization and phase I study in normal subjects
Macfarlane et al. Safety, pharmacokinetic and dosimetry evaluation of the proposed thrombus imaging agent 99mTc-DI-DD-3B6/22-80B3 Fab′
Meckel et al. Reduced renal uptake of various radiopharmaceuticals with sodium paraaminohippurate coadministration in a rat model
Singh et al. A simplified kit for instant preparation of technerium-99m human immunoglobulin-G for imaging inflammatory foci
Kurizaki et al. Potentiation of radioimmunotherapy with response-selective peptide agonist of human C5a
Reynolds et al. Radiohalogenation of monoclonal antibodies: Experiences with radioiodination of monoclonal antibodies for radioimmunotherapy
Ballantyne et al. Experience with a commercial preparation of 125I-labelled human albumin for study of albumin metabolism
Tsopelas et al. Evaluation of 99mTc‐immunoglobulins for imaging infection in the rat
Broer et al. 89Zr-brentuximab development for whole-body PET imaging of patients with CD30 positive lymphoma, eligible for brentuximab-vedotin therapy
Chopra 99m Tc-Labeled rituximab, a chimeric murine/human anti-CD20 monoclonal antibody [99m Tc] Rituximab

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050527

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050527

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20070706

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090310

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090403

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120410

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130410

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140410

Year of fee payment: 5

LAPS Cancellation because of no payment of annual fees